Coronavirus vaccine developer Novavax (NASDAQ: NVAX) may not have won the race to commercialize its jab first, but it’s undeniably a winning stock. Up about 50% in the past 12 months, the company’s rise to prominence has no doubt benefited its investors.
So it’s worthwhile thinking about the growth trajectory of innovative businesses like Novavax. Today, I’ll be taking a look at how much an early investment in it would be worth right now — and perhaps what lessons investors can learn.
Image source: Getty Images.